Abstract:Lack of robust activation of Stimulator of Interferon Genes (STING) pathway and subsequent induction of type I IFN responses is considered a barrier to antitumor immunity in acute myeloid leukemia (AML). Using common human AML cell lines as in vitro tools to evaluate the efficacy of novel STING agonists, we found most AML lines to be poor producers of IFNs upon exposure to extremely potent agonists, suggesting cell-intrinsic suppression of STING signaling may occur. We observed unexpected patterns of response that did not correlate with levels of STING pathway components or of known enzymes associated with resistance. To identify a genetic basis for these observations, we cloned and sequenced STING from the cDNA of human AML cell lines and found both frequent mutations and deviations from normal RNA splicing. We identified two novel spliced isoforms of STING in these lines and validated their expression in primary human AML samples. When transduced into reporter cells, these novel STING isoforms exhibited complete insensitivity to agonist stimulation. These observations identify alternative splicing as a mechanism of STING pathway suppression and suggest that most AML silences the STING pathway through direct modification rather than through engagement of external inhibitory factors. Significance: We find that AML acquires resistance to innate immune activation via the STING pathway through aberrant splicing of the STING transcript including two novel forms described herein that act as dominant negatives. These data broaden understanding of how cancers evolve STING resistance, and suggest that the AML tumor microenvironment, not the cancer cell, should be the target of therapeutic interventions to activate STING.

Non-canonical isoforms of the mRNA polyadenylation factor WDR33 regulate STING-mediated immune responses

WDR33 alternative polyadenylation is dependent on stochastic poly(a) site usage and splicing efficiencies

A Novel Transcript Isoform of STING That Sequesters Cgamp and Dominantly Inhibits Innate Nucleic Acid Sensing

Progress in innate immunity signaling molecule STING

The Alternatively Spliced Isoforms of Key Molecules in the cGAS-STING Signaling Pathway

Distinct Dynamical and Conformational Features of Human STING in Response to 2'3'-cGAMP and c-di-GMP.

Epigenetic Regulation of Alternative Splicing.

RNA Binding Proteins that Mediate LPS-induced Alternative Splicing of the MyD88 Innate Immune Regulator

An alternatively spliced STING isoform localizes in the cytoplasmic membrane and directly senses extracellular cGAMP

Activated STING: an Ion Channel to Trigger Non-Interferon-related Functions

The Streptococcus Mutans Irva Gene Encodes a Trans -Acting Riboregulatory Mrna

STING Directly Recruits WIPI2 for Autophagosome Formation During STING-induced Autophagy.

Post-Translational Modifications of cGAS-STING: A Critical Switch for Immune Regulation

Pre-mRNA fate decision safeguards the fidelity of the inflammatory response

Identification of Nonfunctional Alternatively Spliced Isoforms of STING in Human Acute Myeloid Leukemia

Regulating STING in health and disease

Post-Translational Modifications of STING: A Potential Therapeutic Target

RNA Targets Ribogenesis Factor WDR43 to Chromatin for Transcription and Pluripotency Control.

m6A-mediated modulation coupled with transcriptional regulation shapes long noncoding RNA repertoire of the cGAS-STING signaling

Transcription-independent regulation of STING activation and innate immune responses by IRF8 in monocytes

eIF3d: A driver of noncanonical cap–dependent translation of specific mRNAs and a trigger of biological/pathological processes